Potential nephroprotective effects of glucose

Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1) are hormones released in the intestine in response to the intake of nutrients, and they can stimulate ...

The main incretins are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Additional to the pancreas, receptors for GLP-1 are widely distributed in various organs, causing positive effects on endothelial function and vascular atherogenesis.
PDF Nephroprotective Properties of the Glucose

It was later renamed to glucose-dependent insulinotropic polypeptide because its insulinotropic effects were observed at physiological levels. En-teroendocrine K cells located in the small intestinal epithelium secrete GIP into circulation after oral food ingestion [43].
Journal Article Summary The article examines the nephroprotective effects of two incretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), particularly focusing on their combined use as receptor agonists in treating type 2 diabetes mellitus (T2DM). This topic is significant because diabetes is a leading cause of chronic kidney disease, with a ...

PDF Nephroprotective Properties of the Glucose
cardiorenometabolic effects . The main incretins are glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Additional to the pancreas receptors for GLP-1 are widely distributed in various organs, causing positive effects on endothelial function and vascular atherogenesis. Along with glycemic con
The nephroprotective properties of dual GIP and GLP-1 receptor agonists as a new drug to treat type 2 diabetes are presented and preliminary results suggest that tirzepatide improves kidney outcomes in adults with type 1 diabetes with increased cardiovascular risk. Diabetes mellitus is the leading cause of chronic kidney disease, and about 30-40% of patients with diabetes will develop kidney ...
(PDF) Nephroprotective Properties of the Glucose
A significant nephroprotective effect of novel antidiabetic drugs, namely sodium- glucose cotransporter 2 inhibitors (SGLT2-I) and glucagon-like peptide 1 receptor agonists (GLP1-RA), has been ...
This review presents a compelling convergent model for the nephroprotective effects of SGLT2 inhibitors, while acknowledging several limitations that are essential for contextualizing the findings and guiding future research.

Key Details About Potential Nephroprotective Effects Of Glucose Dependent Insulinotropic
Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin-based therapies that were initially developed for managing type 2 diabetes. These agents enhance insulin secretion in a glucose-dependent manner and inhibit glucagon release, which helps control hyperglycemia without inducing significant hypoglycemia. 1 Additionally, GLP-1 receptor agonists promote weight loss by reducing appetite ...








Glucagon-like peptide-1 (GLP-1) receptor agonists are incretin-based therapies initially developed for the management of type 2 diabetes. In addition to improving glycemic control and promoting weight loss, these agents have demonstrated cardiovascular and potential renal benefits. This review explores the mechanisms by which GLP-1 receptor agonists may exert renoprotective effects , including ...